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Abstract: Heart failure (HF) is a clinical syndrome characterized by significant impairment of cardiac ventricular function. Atrial fibril-
lation (AF) is the most commonly observed sustained arrhythmia in clinical practice. Both HF and AF are associated with increased mor-
bidity and mortality and their prevalence increases with age. Approximately 50% of patients with moderate HF die due to ventricular fib-
rillation that leads to sudden cardiac death. Patients with AF exhibit increased mortality due to HF and stroke. HF and AF often co-exist, 
and the development of the other condition further deteriorates prognosis. Both chronic HF and AF lead to structural and electrophysi-
ological changes in the heart called remodeling, modifying therapeutic targets including those for antiarrhythmic intervention. Current 
pharmacological treatment of arrhythmias has major limitations due to low efficacy and serious adverse effects. In this review, the main 
aspects of electrical remodeling in HF and AF are discussed along with possible novel targets identified for future pharmacological 
antiarrhythmic therapy. 
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I. OVERVIEW AND CURRENT STATUS  
Epidemiology of Heart Failure, Atrial Fibrillation and their 
Combination 
 Heart failure (HF) is a clinical syndrome resulting from a wide 
range of cardiovascular disorders, featuring significant impairment 
of cardiac function that leads to reduced ventricular filling or ejec-
tion of blood. HF markedly reduces health-related quality of life 
[1], causes significant morbidity and high mortality and represents 
an enormous economic burden for the health care system [2]. The 
incidence of HF is increasing with age, with 20 per 1000 persons 
65-69 years old and more than 80 per 1000 persons older than 85 
[3] and its prevalence is increasing in a continuously aging popula-
tion [2]. In spite of the significant advances in the treatment of HF, 
mortality rates remain poor at approximately 50% of patients dying 
within 5 years of diagnosis [4]. Serious ventricular arrhythmias are 
common in HF [5] and approximately 50% of HF patients die due 
to ventricular fibrillation leading to sudden cardiac death (SCD), 
the rate of which is several times higher in HF patients compared to 
the general population [6]. In addition to severe ventricular ar-
rhythmias, atrial arrhythmias often develop in heart failure. Brady-
cardia can develop due to sinoatrial function impairment [7] that 
can exacerbate cardiac dysfunction [8], can lead to syncope and 
haemodynamic collapse and can be resolved by application of im-
plantable devices [9]. 
 Atrial fibrillation (AF) is the most common sustained arrhyth-
mia and it is associated with significant morbidity and mortality, 
especially due to the increased risk of heart failure and stroke [10-
12]. The prevalence of AF increases with age, with 0.5% of patients 
affected in the 50 year old range, ~10% over the age of 80 [13] and 
the prediction is that it would increase in the future [14]. Heart fail-
ure and atrial fibrillation are often diagnosed in the same patient, 
and those with HF are more likely to develop AF compared to the  
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general population [15]. The presence of AF in HF patients with 
either preserved or reduced left ventricular function carries an in-
creased risk for all-cause mortality [16]. As the New York Heart 
Association (NYHA) functional classification based severity of HF 
increases, the prevalence of AF also increases [for a review see 
[17]. In patients with HF or AF, the development of the other con-
dition leads to further deterioration of an already poor prognosis. 
The analysis of the temporal relationship of AF and HF in patients 
from the Framingham Heart Study revealed that in patients with 
HF, later development of AF was associated with increased mortal-
ity both in men and women [15]. It is therefore no coincidence that 
AF and HF were called the “two new epidemics of cardiovascular 
disease” [18]. Why do AF and HF so often co-exist? Many cardio-
vascular diseases are common risk factors for both HF and AF de-
velopment [19]. These conditions (e.g. hypertension, valvular heart 
disease, coronary artery disease etc.) may eventually lead to struc-
tural and electrophysiological remodeling [20] and chronic neuro-
hormonal activation that promote the development of both AF and 
HF [21]. In addition, once AF is present, it can facilitate HF due to 
rapid activation of the ventricles leading to tachycardia induced 
cardiomyopathy and maladaptive remodeling of the myocardium 
[22]. Furthermore, AF by itself is associated with decreased cardiac 
output [23]. Heart failure, on the other hand, can promote AF by 
increasing atrial pressure and atrial dilatation [24], by inducing 
atrial fibrosis [25], by its chronic activation of the renin-
angiotensin-aldosterone system that leads to further structural and 
electrophysiological remodeling.  
Pharmacological Treatment of AF in HF 
 Current pharmacological treatment options for the management 
of AF are sub-optimal, since high rates of AF recurrence are ob-
served following cardioversion using currently available drugs [26-
28] and they have even more limited efficacy in patients with per-
sistent/permanent AF and remodeled atria. Furthermore, the major-
ity of these drugs were developed for the treatment of ventricular 
arrhythmias, therefore their ventricular electrophysiological effects 
can lead to pro-arrhythmic ventricular side effects. Therefore there 
is an unmet need for more efficacious and safer pharmacological 
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management of AF [29]. The use of antiarrhythmic agents for the 
management of AF in patients with HF is even more limited, since 
the mortality increasing pro-arrhythmic side effects of these drugs 
in HF are of particular concern. Similar to other patient populations 
with AF, the issue as to whether rhythm control or rate control 
should be pursued in HF patients with AF was studied in the Atrial 
Fibrillation and Congestive Heart Failure (AF-CHF) trial [30]. 
Rhythm control has not been found to be superior to rate control in 
patients with HF who develop AF subsequently, in fact, rate control 
was suggested as the primary approach to manage AF in HF pa-
tients [30]. It is not known, however, to what extent the possible 
pro-arrhythmic side effects of antiarrhythmic drugs negated the 
advantages of sinus rhythm maintenance in this study. Unless con-
traindicated, beta-adrenergic blocker drugs are recommended for 
ventricular rate control due to their beneficial effects on morbidity 
and mortality in HF patients, in combination with digoxin in case of 
reduced left ventricular function [31-33]. When ventricular rate 
control cannot be achieved by pharmacological means, atrioven-
tricular node ablation followed by cardiac resynchronization ther-
apy (CRT) device implantation is often performed [34-35]. 
 In contrast, patients with AF, where HF has developed as the 
consequence of AF, rhythm control strategies should be chosen 
[33]. In HF patients with preserved systolic function, AF leads to a 
more severe functional class of HF and reduced quality of life, and 
to worse diastolic function compared to those in sinus rhythm [36]. 
In HF patients, however, the number of antiarrhythmic drugs that 
can be safely administered is very limited. For rhythm control of 
AF, Class IC compounds should be avoided in patients with struc-
tural heart disease [37], due to considerations based on the results 
of the Cardiac Arrhythmia Suppression Trial (CAST), where Class 
IC drugs increased mortality of patients with ischemic heart disease 
and impaired left ventricular function [38-39]. The Class IA drug 
quinidine increased the risk of death threefold when used in AF 
patients for maintenance of sinus rhythm following cardioversion 
[40]. Some Class III antiarrhythmic drugs are also used and have 
proven useful for the restoration and maintenance of sinus rhythm 
in patients with AF [41]. However, so far only amiodarone and 
dofetilide have exhibited neutral influence on mortality in patients 
with HF: amiodarone prevented the recurrence of AF far more ef-
fectively than propafenone and D, L-sotalol while showing no det-
rimental effects in patients with reduced left ventricular ejection 
fraction [26]. Dofetilide did not alter all-cause mortality in patients 
with left ventricular dysfunction but improved the conversion rate 
of AF to sinus rhythm in the DIAMOND-CHF trial [42]. Impor-
tantly, dofetilide improved mortality in HF patients who had normal 
QTc intervals before drug treatment compared to those who had a 
prolonged QTc [43]. D, L-sotalol should be avoided since it in-
creases the incidence of Torsades de Pointes (TdP) arrhythmias in 
HF [44]. Antiarrhythmic compounds with selective IKr blocking 
properties (Class III effect) markedly prolong the action potential, 
leading to proarrhythmic adverse effects via early afterdepolariza-
tion induction and enhancement of ventricular dispersion of repo-
larization, prerequisites for the development of TdP [45]. Thus, the 
multi-channel blocker amiodarone remains the most effective 
antiarrhythmic compound and the drug of choice for the majority of 
HF patients with AF, however, its chronic use is associated with 
significant extracardiac side effects [26]. Although amiodarone 
seems to be the least pro-arrhythmic drug among antiarrhythmic 
drugs administered for AF [46], it may increase sudden cardiac 
death risk in patients with advanced HF and with a history of previ-
ous TdP arrhythmia [47]. The majority of the extracardiac toxicity 
of amiodarone were hoped to be avoided with retained antiarrhyth-
mic activity by the development of dronedarone, a newer amiodar-
one derivative lacking the iodine moiety, with fewer pulmonary and 
thyroid side effects [48-49]. The disappointing results of the PAL-
LAS trial, however, indicated higher rates of hospitalization, heart 
failure episodes, stroke and all cause mortality in patients random-
ized to dronedarone [50-52]. Therefore, dronedarone is now rec-
ommended to be used only in paroxysmal AF or following car-
dioversion of persistent AF in patients with preserved left ventricu-
lar function, and it is contraindicated to use in patients with NYHA 
IV class HF, and in patients with a prior episode of acute decom-
pensation of HF, especially with left ventricular ejection fraction 
<35% [53]. 
 Atrial fibrillation carries a significant risk for thromboembolic 
events irrespective of the type of AF (paroxysmal, persistent or 
permanent) [11] and their rate increases with age [54], therefore, 
stroke prevention and antithrombotic therapy are major concerns 
for AF management. However, antithrombotic therapy in AF is not 
the subject of this review and the reader is referred to some excel-
lent recent reviews and to the latest guidelines [41, 53, 55-56]. 
Pharmacological Management of Ventricular Arrhythmias in 
HF 
 Cardiac ventricular arrhythmias significantly contribute to mor-
bidity and mortality in HF. However, most antiarrhythmic agents 
have been shown to increase mortality in patients with HF [57-58], 
and the proarrhythmic effects of Class I and III antiarrhythmic 
compounds are even more pronounced in HF patients [37-38, 40, 
58]. Therefore, Class I sodium channel blocking drugs and the 
Class III drugs d-sotalol and dronedarone [50] should not be admin-
istered in HF, and antiarrhythmic drugs in general are listed as 
compounds that may worsen HF in the current HF management 
guidelines, including Class IV Ca2+ channel blockers [33]. At the 
time of this review, only the multi-channel blocker amiodarone and 
dofetilide (Class III) can be recommended for arrhythmia manage-
ment in HF patients due to their neutral influence on mortality as 
observed in the GESICA, CHF-STAT and DIAMOND clinical 
trials [42, 59-61]. However, dofetilide can cause marked QT inter-
val prolongation and can provoke TdP, therefore dofetilide treat-
ment initiation is a mandatory in-hospital procedure in all patients 
[62-63]. Due to these safety concerns dofetilide is not approved in 
some countries. 
Non-Pharmacological Arrhythmia Management in HF 
 With the limited efficacy and significant safety concerns re-
garding antiarrhythmic drug administration for AF treatment [26-
27, 64], non-pharmacological approaches to AF management are 
steadily gaining ground and offer benefits to selected populations of 
patients. In approximately 10-15 % of patients with AF, appropriate 
ventricular rate control cannot be obtained pharmacologically [65]. 
Radiofrequency catheter ablation of the AV node followed by im-
plantation of a permanent pacemaker can be a solution in these 
cases, improving quality of life, rate control, ventricular function 
and exercise capacity [66]. Rhythm control by catheter ablation has 
been used increasingly and has been found to be superior in main-
taining sinus rhythm compared to antiarrhythmic drugs [67]. The 
discovery of the role of pulmonary vein sleeve ectopic triggers in 
the development of AF [68] has led to the establishment of the 
pulmonary vein isolation technique [69]. This approach has been 
shown to be feasible in patients with AF and decreased ventricular 
function and heart failure, leading to an increase in ejection fraction 
and improvement in quality of life [70-72]. Ongoing clinical trials 
will provide more definitive answers on how catheter ablation and 
conventional therapy influences morbidity and mortality in AF 
patients with left ventricular ejection fraction <35% (CASTLE_AF) 
[73] and whether catheter ablation of pharmacological rate or 
rhythm control is superior for reducing total mortality in untreated 
AF patients (CABANA) [74]. The success rate of non-
pharmacological treatment of AF critically depends on appropriate 
patient selection for these procedures, summarized by the recently 
published expert consensus statement [75]. 
 Sudden cardiac death due to ventricular fibrillation is a leading 
cause of death among HF patients [6]. However, for the treatment 
of venricular arrhythmias in HF, due to the significantly increased 
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arrhythmia susceptibility observed in HF patients and because of 
the proarrhythmic adverse effects of currently available antiar-
rhythmic drugs, the use of pharmacological agents is very limited. 
Serious proarrhythmic adverse effects and increased mortality are 
associated with Class IA, IC and Class III antiarrhythmic drug ad-
ministration in patient populations with impaired ventricular func-
tion [57-58, 76]. Among Class III agents, most likely due to its 
multi-channel blocking properties, amiodarone has been the most 
effective and relatively safe drug with the smallest proarrhythmic 
potential, causing TdP in approximately 1% of cases [45]. How-
ever, in patients with previous history of TdP amiodarone is not 
considered safe and should not be used [47]. 
 The implantable cardioverter defibrillator (ICD) detects and 
terminates life threatening serious ventricular tachyarrhythmias and 
was introduced for the primary and secondary prevention of sudden 
cardiac death in high-risk patients including those with severe left 
ventricular dysfunction [77-79]. In order to compare the ability of 
amiodarone and single-lead, conservatively programmed ICD to 
reduce the risk of death from any cause, the Sudden Cardiac Death 
in Heart Failure Trial (SCD-HeFT) was conducted involving 2521 
patients with mild to moderate heart failure [79]. The main conclu-
sion of the trial was that in patients with left ventricular ejection 
fraction  35%, in NYHA functional class II and III, amiodarone 
did not influence survival, while ICD therapy reduced the relative 
risk of death by any cause by 23% [79]. The authors compared their 
results to previous HF trials studying the effects of ICD therapy on 
mortality and suggested that ICD programming was critical to the 
final outcome. Indeed, in the Amiodarone versus Implantable Car-
dioverter Defibrillator (AMIOVIRT) Trial no benefit was offered 
by ICD therapy over amiodarone therapy, as mortality and quality 
of life were similar in the two groups involving 103 patients with 
non-ischaemic dilated cardiomyopathy, non-sustained ventricular 
tachycardia and with left ventricular ejection fraction  35% [80]. 
In the DEFINITE trial comprising 458 patients, again, no beneficial 
effect on all cause mortality, however, a significant reduction in 
arrhythmia related sudden cardiac death was observed with ICD 
application when compared to standard therapy with beta-
adrenergic blockers and ACE inhibitors in patients with severe, 
non-ischaemic dilated cardiomyopathy [81]. In these studies, differ-
ent thresholds for pacing, different heart rate prompting, different 
devices (single-, dual or triple-chamber) were applied, emphasizing 
the importance of device settings and type selection in different 
subsets of patients with HF. A detailed and comprehensive review 
on the effectiveness of ICDs for primary prevention of sudden car-
diac death has been published very recently [82]. 
 Cardiac resynchronization therapy (CRT) devices represent one 
of the most promising developments for the treatment of advanced 
systolic HF [83-84]. It was recognized that patients with severe 
heart failure frequently had myocardial regions with delayed activa-
tion and contraction resulting in dyssynchrony and these alterations 
influenced mortality and conduction delay was a prognostic marker 
in patients with heart failure [85]. Cardiac resynchronization ther-
apy aims at the synchronization of electrical activation of the left 
and right sides of the heart thereby improving cardiac output [86-
87]. CRT therapy is now indicated in HF patients with NYHA class 
II to IV symptoms in spite of adequate therapy, left ventricular 
ejection fraction  35% and QRS width  120 ms [88]. Cardiac 
resynchronization therapy has been found to reduce mortality and to 
promote reverse left ventricular remodeling as well as to improve 
quality of life [89] and these beneficial effects were maintained 
during long term follow-up [90]. Similar results were observed in 
patients with moderate (NYHA class II) heart failure [91] and even 
mild, NYHA class I heart failure, although risks should be weighed 
carefully against benefits in this group of patients [92]. The effect 
of CRT therapy on arrhythmias is not fully elucidated. Previously it 
was accepted that CRT did not decrease AF incidence [93], how-
ever, some studies suggest that CRT is associated with increased 
resumption of sinus rhythm in patients with persistent AF [94] and 
even permanent AF [95-96]. Although some case reports described 
CRT provoking ventricular arrhythmias [97-98], others reported 
that CRT reduced the burden of ventricular arrhythmias [99], and 
the analysis of two large CRT trials did not find an increase in po-
lymorhic VT or a decrease in monomorphic VT in 880 patients 
receiving CRT therapy [100]. Cardiac resynchronization and ICD 
therapies are frequently combined as cardiac resynchronization 
therapy with a defibrillator (CRT-D) [88, 101]. Upgrading ICD 
therapy to CRT-D therapy in HF patients due to worsening of 
symptoms can significantly reduce the frequency of ventricular 
tachycardia, fibrillation and device shocks [102]. 
 It should be noted that cardiac electronic device implantations 
are not without complications, moreover, a higher than expected 
complication risk was identified in a Danish study involving almost 
6000 patients receiving permanent pacemakers, ICDs, CRT and 
CRT-D devices, at almost 10% of patients experiencing at least one 
complication [79, 103]. A particularly troublesome complication of 
CRT device implantation is the markedly increased risk of infection 
that can be difficult to manage and is associated with significant 
morbidity [104]. 
 Not all patients who are candidates for CRT respond to therapy, 
and the exact correlation between QRS widening and developing 
dys-synchrony needs to be further evaluated, the use of CRT in 
patients with AF is a subject to controversy [9, 105]. In HF patients 
with reduced ejection fraction, recurrent ventricular arrhythmias 
and ICD shocks are observed, leading to significant morbidity and 
mortality as well as reduced quality of life (for a recent review see 
[106]). Optimal programming of ICD decreases the number of 
shocks [107], and ICD application reduces sudden cardiac death 
[82], however, these devices do not reduce ventricular arrhythmia 
incidence in HF patients. For the management of recurrent ar-
rhythmias and reduction of ICD shocks in HF patients with reduced 
ejection fraction and ICD, adjuvant antiarrhythmic therapy is war-
ranted. In this regard, amiodarone has been found to be most effec-
tive for ventricular arrhythmia treatment and shock reduction. 
However, the use of amiodarone is limited by serious extracardiac 
adverse effects [108]. 
Need for New, Safer and More Efficacious Antiarrhythmic 
Compounds 
 Based on the overview above, there is a clear unmet need for 
novel antiarrhythmic drugs for the treatment of atrial fibrillation 
and serious ventricular arrhythmias in HF patients, that are safer 
and more efficacious compared to currently available compounds. 
Some promising new drugs, like tedisamil, azimilide, dronedarone 
and vernakalant have not fulfilled expectations for pharmacological 
atrial and/or ventricular arrhythmia management in the setting of 
heart failure with reduced left ventricular function. 
 In the following part of this review, some of the main aspects 
and mechanisms of the increased arrhythmia susceptibility observed 
in HF are described, followed by the discussion of novel and prom-
ising targets and investigational compounds for antiarrhythmic 
intervention in HF. 
II. MYOCARDIAL REMODELING: CREATING AR-
RHYTHMIA SUBSTRATE AND TRIGGERS IN HEART 
FAILURE 
 In an attempt to maintain proper cardiac function and intracellu-
lar homeostasis and in response to pathophysiological processes 
involved in cardiovascular diseases, including HF and AF devel-
opment, a number of electrophysiological and structural changes 
are observed in the heart, collectively described as myocardial re-
modeling. These alterations are partly adaptive in nature, however, 
when maintained for longer periods they can lead to further deterio-
ration of cardiac function, and importantly, can significantly con-
tribute to arrhythmia development and maintenance. This review 
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mainly focuses on the arrhythmogenic consequences of electrical 
remodeling and their possible exploitation for therapy, thus the 
reader is recommended to refer to previous articles discussing struc-
tural remodeling [109-110]. The following sections will deal with 
three main areas of electrical remodeling in HF and AF: aspects of 
myocardial repolarization, conduction and impulse generation re-
modeling. 
Remodeling of Atrial and Ventricular Action Potential and 
Repolarization in AF and HF 
 The cardiac action potential is a highly regulated and coordi-
nated function of different inward and outward ionic currents and 
exchangers ensuring proper electrical and electromechanical func-
tion of different regions of the heart [111-112]. In a number of 
pathological settings, including heart failure and atrial fibrillation, 
fundamental changes appear in the duration and shape of the action 
potential. Some of these changes are adaptive: it is consistently 
found that action potential duration is prolonged in HF [113-115] 
and it may serve to compensate for impaired Ca2+ transients and 
reduced contractility in failing cardiac myocytes by increasing Ca2+ 
load and subsequent release thereby improving cell contractility 
(Fig. 1).  
 Excessive prolongation of repolarization, however, can lead to 
the development of early afterdepolarizations (EADs) [115, 117] 
mainly due to recovery of ICa, L from inactivation [118]. EADs can 
provoke Torsades de Pointes polymorphic ventricular tachycardia 
(TdP) in HF patients [119]. TdP leads to syncope and often reverts 
back to sinus rhythm spontaneously, however, TdP can degenerate 
into ventricular fibrillation that leads to sudden cardiac death with-
out intervention [118]. Action potential prolongation in HF is due to 
the remodeling of ion channels carrying inward and outward ionic 
currents.  
 Changes in inward currents include the increase of the slowly 
inactivating, late sodium current (INa, late) that contributes to APD 
prolongation and arrhythmogenesis in HF [120-122]. Intracellular 
calcium handling is significantly influenced by HF on several lev-
els. The L-type calcium current (ICa, L) has been mainly reported to 
be unchanged in experimental HF models and humans [123-125] or 
decreased in humans [126]. However, sarcoplasmic reticulum (SR) 
Ca2+ ATPase (SERCA) is downregulated, contributing to decreased 
SR Ca2+ content and increased diastolic Ca2+ concentration [127]. 
The decreased SERCA function impairs Ca2+ removal from the 
cytoplasm and may be the cause for the observed Na+-Ca2+ ex-
changer (NCX) upregulation in HF [128]. The electrogenic NCX 
exchanges 3 Na+ for one Ca2+ through the plasma membrane and its 
main function is the removal of excess intracellular Ca2+ during 
diastole, however, the exchanger can work in both forward (Ca2+ 
extrusion) and reverse (Ca2+-influx) modes, depending on actual 
membrane potential, intracellular and extracellular Na+ and Ca2+ 
concentrations [129]. Since the NCX is responsible for net inward 
current during the later phase of the action potential, its upregula-
tion may importantly contribute to APD prolongation and arrhyth-
mogenic delayed afterdepolarization (DAD) development in HF 
[130]. 
 Electrical remodeling includes profound changes in voltage-
gated potassium channel expression in HF. Although experimental 
animal and human studies show some differences, the most consis-
tent changes are downregulation of the transient outward current 
(Ito) [123, 131], the slowly activating component of the delayed 
rectifier (IKs) [117, 125, 132] and inward rectifier (IK1) [117, 133], 
while with the rapid component of the delayed rectifier (IKr) most 
studies reported no changes [117, 125, 132].  
 Therefore, in HF, the repolarization capacity of ventricular 
myocytes is significantly reduced due to the downregulation of 
different repolarizing K+ channels and increased INa, late, promoting 
EAD and/or DAD formation and arrhythmia generation, as de-
scribed above. Also, decreased repolarization capacity means that 
repolarization reserve [134] is markedly impaired in failing ven-
tricular myocytes. Repolarization reserve refers to the backup 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Schematic illustration of action potentials, Ca2+ transients and cell shortening (contraction) from normal (A) and failing (B) cardiomyocytes showing 
the compensatory changes in action potential duration by electrical remodeling (indicated by violet lines) in HF. Arrows indicate changes in current densities. 
Reproduced with permission from [116]. 
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mechanisms of repolarization in the heart, namely the decreased 
function (by congenital or acquired means) of a repolarizing current 
can be compensated for by an increase in other potassium currents 
[135-136]. Impaired repolarization reserve importantly contributes 
to increased arrhythmia susceptibility in HF patients. In clinical 
practical terms it means that not only antiarrhythmic drugs with 
strong potassium channel blocking properties (Class IA, IB and 
Class III) can provoke TdP, VF and sudden cardiac death in HF 
patients, but the application of non-cardiovascular drugs that pos-
sess weaker K+ current inhibitory effects, including some antibiot-
ics [137], antimycotics [138], antihistamines [139], antipsychotics 
[140], NSAIDs [141], even dietary constituents [142], K+-losing 
diuretics etc., can further interfere with repolarization [143] and can 
lead to unexpected and serious ventricular arrhythmia development 
in this patient population. Importantly, the presence of repolariza-
tion prolonging genetic mutations responsible for different forms of 
long QT (LQT) syndromes can also exacerbate ventricular ar-
rhythmias in HF. 
 In clinical and experimental settings, the longer AF persists, the 
harder it becomes to convert AF back to sinus rhythm. This phe-
nomenon was first described by Allessie and colleagues with the 
now famous expression: “atrial fibrillation begets atrial fibrilla-
tion”, in their work based on a goat model of AF [144]. The longer 
AF is present, the more pronounced changes appear in atrial myo-
cardial structure, electrophysiology and function (Fig. 2). 
 As (Fig. 3) illustrates, in contrast to the ventricular AP changes 
in HF, atrial fibrillation associated remodeling of the atria results in 
atrial AP shortening and triangulation [145], that leads to shortened 
atrial effective refractory period and creation of an arrhythmia sub-
strate that is responsible for further maintenance of AF. 
 Again, the remodeling of the AP, at least in part, is the result of 
compensatory changes in atrial ion channel expression and func-
tion. Rapid atrial rates during AF lead to Ca2+ overload of atrial 
myocytes [146-147], and the consistent finding of reduced ICa, L 
[148] that protects the cells from this Ca2+ overload and also con-
tributes to APD and refractoriness abbreviation [149-150]. These 
protective changes, however, become detrimental over longer peri-
ods of time since the shortened APD and refractoriness makes the 
atria more vulnerable to AF initiation and favours the maintenance 
of the arrhythmia [144]. 
 Only small, about 10 to 20% changes in INa density in atrial 
myocytes of patients with chronic AF have been detected [151-
152]. In atrial tachycardia induced AF animal models, however, a 
marked decrease in INa was observed [153]. Decreased INa can slow 
atrial conduction and may further shorten wavelength [153] already 
abbreviated by APD and refractoriness shortening, and a shorter 
wavelength increases the number of atrial re-entry circuits [154]. 
Some in vitro animal experimental data also suggests that an in-
creased INa, late might play a role in atrial arrhythmia generation 
[155]. Data regarding NCX expression are inconsistent: a signifi-
cant increase in protein expression [156] and no change in NCX 
mRNA have been both described in AF [157]. Voltage-gated potas-
sium currents exhibit significant changes as part of the electrical 
remodeling in the atria, including an approximately 60% decrease 
in Ito [149, 151], a decrease in the atrial specific acetylcholine-
activated K+ channel (IK, ACh) expression [158], but an increased 
constitutively active (without cholinergic ligand stimulation) IK, ACh 
component [159], however, IK1 upregulation is consistently present 
in patients with AF [160]. The increases in IK1 and constitutive  
IK,ACh make the membrane potential more hyperpolarized and 
shorten the APD, therefore contributing to re-entry rotor stabiliza-
tion [161]. Experimental animal data suggest that IKr and IKs are 
unaltered [162], and the sparse functional data from humans indi-
cated increased IKs [163]. The atrial specific ultrarapidly activating 
IKur [164] expression may be either decreased [163, 165], or unal-
tered [149, 151]. Importantly, if IKur expression/activity is decreased 
this could potentially hinder the further development of the numer-
ous IKur inhibitory compounds that have been developed for the 
atrial specific treatment of AF [166-167]. Cardiac ATP-sensitive 
potassium channels (KATP) [168] are voltage-independent potas-
sium channels linking cell metabolism to membrane excitability, 
they are predominantly closed under normoxic conditions and are 
opened by hypoxia and metabolic stress such as elevated workload 
[169], considerably shortening the action potential. KATP channels 
are responsible for the activation of several cardioprotective 
mechanisms [170]. Studies on expression of KATP in AF are incon-
clusive, with some studies showing no change, increase or decrease 
in expression [158, 171-172]. Furthermore, while expression of 
KATP channels may be unaffected, as increased workload may acti-
vate KATP channels, the relative activity of these channels may ac-
tually be increased in HF and/or AF. However, this remains to be 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Representative atrial electrograms recorded from a chronically instrumented goat. The duration of burst-induced AF episodes were prolonged when 
preceding AF was maintained for longer time periods (24h and then 2 weeks). Upper trace: before the burst, the goat was in sinus rhythm and the induced AF 
terminated in 5 seconds. Middle trace: The burst induced AF terminated in 20 seconds after 24 h preceding AF. Bottom trace: Burst induced AF did not termi-
nate when the preceding AF lasted for 2 weeks. Reproduced from [144] with permission. 
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determined conclusively. Moreover, several cardiac KATP channel 
subunit mutations have been found to underlie some rare congenital 
forms of idiopathic AF [173]. Therefore, KATP channels may play a 
role in the development and/or maintenance of AF in HF, where 
continuously elevated adrenergic stimulation, increased workload 
and myocardial ischaemia are common features of these diseases.  
Remodeling of Conduction in AF and HF 
 Conduction abnormalities are important contributors to in-
creased arrhythmia susceptibility and creation of an arrhythmia 
substrate in both HF and AF. Indeed, as already mentioned, reduced 
intraventricular conduction is prognostic for heart failure [85]. Im-
pairment of gap junction function has been found in different forms 
of human cardiomyopathies and HF [174], mostly attributed to 
downregulation and altered distribution of ventricular gap junction 
constituent connexin43 (Cx43) [175-177]. These changes are fur-
ther exacerbated by ischaemia increasing the chance for the devel-
opment of serious ventricular arrhythmias and sudden cardiac death 
[178]. While increased expression of Cx40 and its lateralization is 
observed in AF, data regarding Cx43 expression and localization 
are not conclusive, probably due to different patient populations 
studied [179-180]. Interestingly, in a recent human study, the appli-
cation of the beta-adrenergic blocker metoprolol has been found to 
antagonize the detrimental changes in Cx43 localization and subse-
quent conduction changes in patients with AF [181]. The detailed 
discussion of this topic is beyond the scope of this paper and read-
ers are referred to a comprehensive review on this topic published 
in this issue [182]. 
Remodeling Leading to Increased Triggered Activity 
 In addition to increased arrhythmia susceptibility by the devel-
opment of arrhythmia substrates due to pathological changes in 
repolarization and conduction in HF and AF, an arrhythmogenic 
trigger is required for arrhythmia induction. The hyperpolarization-
activated, cyclic nucleotide-gated pacemaker “funny current” (If), 
encoded by the HCN genes, plays a key role in sinus node pace-
making [183]. Increased expression of HCN2 and HCN4 in human 
ventricular myocytes from HF hearts may contribute to the genera-
tion of abnormal ventricular-triggered activity in HF [184-185]. 
Increased HCN subunit expression has been found also in the atria 
of the failing heart, and increased If in atrial tissue may contribute 
to abnormal ectopic activity in AF [186]. Pulmonary vein foci have 
been identified as sources of initial triggered activity in AF [68, 
187], leading to the development of electrical isolation of these 
pulmonary vein muscle sleeves via catheter ablation. Remodeling 
affecting the ryanodine receptors, SERCA and NCX also play im-
portant roles in the development of arrhythmic triggers in HF [188-
192] and AF [193-195], and the reader is referred to excellent re-
views on these topics in the current issue [196-197]. 
Contribution of Myocardial Ischaemia and Ischaemia-Induced 
Remodeling to the Development of Arrhythmias in Heart Fail-
ure 
 Myocardial ischaemia and infarction can both cause and be a 
consequence of HF and AF, and contribute to arrhythmogenic elec-
trophysiological changes and remodeling via their own distinct 
mechanisms [20, 198]. These mechanisms include increased disper-
sion of repolarization between regions with different degrees of 
ischaemia and different degree of activation of KATP channels [198-
201], impairment of conduction in early ischaemia [202], signifi-
cantly different remodeling of repolarization and conduction in 
non-infarcted versus infarction border zone tissues [20], potassium 
loss from ischaemic cardiac tissue leading to heterogenous mem-
brane potential depolarization of tissues with varying degree of 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Remodeling of the atrial action potential and the underlying alterations of ionic currents and channel subunit expression changes. SR: sinus rhythm; 
AF: atrial fibrillation. Please see text for detailed discussion on elements of atrial electrical remodeling in AF. Reproduced from [110] with permission. 
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ischaemia [203-204]. These electrical and structural changes can 
add to the already complex alterations present due to HF and/or AF. 
III. NOVEL PHARMACOLOGICAL APPROACHES FOR 
THE TREATMENT OF ARRHYTHMIAS IN HEART FAIL-
URE 
 In the final part of this review, the possible antiarrhythmic 
pharmacological modulation of selected promising targets identi-
fied by HF and AF induced remodeling studies are discussed.  
INa, late Inhibitors 
 In addition to the rapidly inactivated component of the NaV1.5 
carried, SCN5A gene encoded human voltage dependent peak so-
dium current (INa), that is responsible for the fast upstroke of the 
cardiac action potential and impulse propagation in the myocar-
dium, a slowly inactivating sodium current component has been 
identified that persists through the action potential plateau [205-
206]. The late sodium current (INa, late) has an amplitude 100 fold 
smaller compared to the peak Na+ current, however, it may contrib-
ute to the plateau phase of the AP and to dispersion of APD in the 
myocardium [207]. Increased INa, late has been observed in several 
cardiovascular diseases, including myocardial ischaemia, angina 
pectoris, congenital long QT syndrome, HF and AF [208-211]. In 
the ventricle, increased INa, late prolongs the action potential duration 
[205, 209, 212] and facilitates EAD generation [212-213], while in 
guinea pig atrial myocytes it was shown to play a role in DAD for-
mation and sustained triggered activity [155]. Therefore, the inhibi-
tion of the INa, late current has been proposed as a promising new 
approach for the treatment of ventricular arrhythmias in HF as well 
as AF management [214-215]. However, any novel compound de-
veloped against this target needs to show considerable selectivity 
for the inhibition of INa, late as opposed to peak INa inhibition to 
avoid adverse effects on myocardial conduction and contractility, 
i.e. to be useful in patients with reduced ventricular function and/or 
structural heart disease. Interestingly, amiodarone, the most effec-
tive antiarrhythmic multichannel blocker drug exhibited a 13-fold 
more potent inhibitory effect on INa, late than on peak INa [216]. Res-
veratrol, a red wine polyphenol with cardioprotective characteristics 
[217] has been shown to possess a 2-fold selectivity for late over 
peak INa inhibition [218]. Ranolazine, a INa, late blocker approved for 
the treatment of angina pectoris [219], is considered to have a 30 to 
40-fold higher INa, late inhibitory potency over peak INa [220]. How-
ever, in canine and human cardiac preparations, ranolazine signifi-
cantly and use-dependently decreased the maximum rate of depo-
larization (Vmax) at a concentration of 10 M, suggesting a peak INa 
inhibiting effect with Class I/B antiarrhythmic characteristics in 
concentrations previously considered to be selective for INa, late inhi-
bition [221]. In guinea pig ventricular myocytes, ranolazine inhib-
ited the increase of INa, late induced by sea anemone toxin ATX-II 
administration [222]. In left ventricular myocytes from failing dog 
hearts, ranolazine reversed abnormalities of repolarization and con-
tractile dysfunction [223]. Recently, ranolazine has been shown to 
reduce the IKr blocker dofetilide induced TdP in dogs with chronic 
atrioventricular block [224], a large animal proarrhythmia model 
featuring impaired repolarization reserve due to downregulation of 
IKs [225]. It should be noted that ranolazine also blocks IKr [226], 
however, its blocking effect is not frequency dependent and recov-
ery from this block is fast [227]. Thus, the antiarrhythmic effects of 
ranolazine were attributed to INa, late inhibition rather than IKr block, 
and the net effect of the drug on the APD was considered to depend 
on the magnitudes of INa, late and IKr in the given situation. Rano-
lazine was shown to cause a slight prolongation of the QT interval 
in patients [228]. In a recent paper in a Langendorff-perfused nor-
mal rabbit heart model (without increased INa, late) 10 M ranolazine 
further increased d-sotalol induced action potential duration prolon-
gation, however, the compound also reduced the incidence of d-
sotalol and low potassium concentration-induced TdP [229]. These 
results strongly suggest that ranolazine has additional electrophysi-
ological effects that may prove to be beneficial or even detrimental 
(further prolongation of repolarization) in certain clinical settings. 
Therefore, compounds with more selective INa, late over peak INa 
effects are desirable and preferably devoid of IKr blocking proper-
ties to prevent ventricular pro-arrhythmic adverse effects in patients 
with HF and/or diseases impairing ventricular repolarization re-
serve. In this regard, a novel, highly selective INa, late inhibitor (100-
fold more potent late current than peak current inhibition), GS-
458967 (GS967; Fig. 4) was synthesized, that did not affect other 
currents [230] and exhibited protective effects against experimental 
ventricular and atrial arrhythmias [231-232]. In a very recent publi-
cation, a novel small molecule targeting multiple mechanisms in-
volved in atrial fibrillation showed a 3-fold higher INa, late inhibition 
over peak INa inhibition, in addition to other ion channel blocking 
properties, and exhibited efficacy against AF in a chronic atrial 
tachypacing induced AF dog model [233]. Another novel INa, late 
inhibitor, F 15845, reduced the incidence of coronary artery ligation 
induced arrhythmias in rats [234]. Based on these data, inhibition of 
INa, late represents a promising approach for the treatment of both 
ventricular and atrial arrhythmias in HF. A more detailed discussion 
of the pathological consequences of increased INa, late and the poten-
tial antiarrhythmic applications of INa, late blockers is the subject of a 
pertinent paper in this issue [235]. 
Potassium Channel Activators 
 As already discussed, APD prolongation is a consistent finding 
in ventricular myocytes from failing animal and human hearts 
[124], and repolarization prolongation is a major cause of serious 
ventricular arrhythmias and sudden cardiac death in HF [236]. Fur-
thermore, increased spatial dispersion of repolarization due to non-
uniform APD prolongation, an important contributor to the creation 
of an arrhythmia substrate was found in HF and cardiac hypertro-
phy [237], that can be further exacerbated by K+ channel blocking 
drugs in these patients due to the different regional and transmural 
distribution of expression of these channels. In theory, there are 
several approaches that can be utilized to limit excessive AP pro-
longation in congenital and acquired long QT via the activation of 
different voltage dependent potassium channels. Below, the effects 
of novel compounds developed for the pharmacological activation 
of IKr, IKs and Ito are discussed. 
 Pharmacological activators of IKr have been the most inten-
sively studied among voltage gated K+ channel activators so far. A 
number of IKr activators have been developed by different compa-
nies in recent years (Fig. 5) [238-240]. NS1643 and NS3623 (by 
NeuroSearch) influence hERG1 inactivation, both causing a right-
ward shift on the inactivation curve of the current [238, 241]. It is 
important to note that NS1643 blocks IKs too, albeit only at slow 
pacing rates [242]. Since IKs plays a critical role in cardiac ventricu-
lar repolarization reserve [243], it is not yet clear how this effect 
influences the antiarrhythmic activity of NS1643. Another hERG1 
channel agonist, RPR260243 (by Sanofi-Aventis), influences chan-
nel deactivation properties [239] and also causes a rightward shift 
on the inactivation curve of the current [244], similarly to the NS 
hERG1 activator compounds. Additional hERG1 activator com-
pounds were developed by Pfizer, PD-118057 and PD-307243 
[240], and the latter has been shown to slow both deactivation and 
inactivation of the channel. ICA-105574 was developed by Icagen 
(later acquired by Pfizer) and was shown to be a potent inhibitor of 
hERG channel inactivation and to shorten action potentials in 
guinea pig ventricular cardiomyocytes [245]. A very recent study 
compared the effects of NS1643 and ICA-105574 in guinea pig 
preparations and found that both compounds shortened action po-
tentials in isolated ventricular cardiomyocytes and QT intervals in 
isolated hearts, however, only ICA-105574 prevented IKr and IKs 
inhibitor induced arrhythmias in isolated hearts [246]. Importantly, 
ICA-105574 exhibited proarrhythmic adverse effects in normal 
hearts when applied in higher concentrations in the same study. 
Although NS1643 did not show antiarrhythmic effects in isolated 
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guinea pig hearts [246], in isolated guinea pig ventricular cardio-
myocytes NS1643 prevented triggering activity due to early after-
depolarizations [242]. NS1643 convincingly exhibited antiarrhyth-
mic activity in two different rabbit models of TdP [247]: in rabbits 
with chronic atrioventricular block and bradycardia [248], and in 
the classical methoxamine-sensitized rabbit model [249]. In a trans-
genic rabbit model of congenital LQT1 syndrome, NS1643 signifi-
cantly shortened the QTc interval, however, it increased the inci-
dence of arrhythmias in this model and the proarrhythmic effect 
was attributed to the excessive repolarization shortening in these 
animals [250]. NS3623 shortened the QTc interval in anesthetized 
and conscious guinea-pigs, and reversed QTc prolongation induced 
by the IKr blocker E-4031 [251]. Interestingly, NS3623 impaired 
conduction in optical mapping experiments in Langendorff-
perfused guinea-pig hearts, however, the authors found that di-4-
ANEPPS, the voltage sensitive dye itself decreased conduction 
velocity, raising the possibly of confounding these results [252]. 
 The slow component of the delayed rectifier potassium current, 
IKs, plays a critical role in cardiac ventricular repolarization reserve 
[136, 243, 253], and its downregulation has been confirmed in ani-
mal models of HF and cardiac hypertrophy as well as in human HF 
[20, 117, 125, 132, 225]. Its pharmacological activation could be 
used for increasing repolarization reserve and for the prevention of 
excessive prolongation of action potentials at slow heart rates in 
clinical settings associated with IKs downregulation and/or dysfunc-
tion. Surprisingly, few compounds have been developed for this 
purpose and very few studies have investigated the effect of IKs 
activators on repolarization. An IKs activator, L-364, 373 (Fig. 6) 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Chemical structures of representative INa, late blockers. 
 
 
 
 
 
 
 
 
 
 
 
Fig. (5). Chemical structures of representative IKr activators. 
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developed more than 15 years ago [254] was shown to enhance IKs 
by causing a negative shift in the voltage dependence of channel 
activation and by slowing channel deactivation [255]. The shorten-
ing of the APD was observed in control, hypertrophied and 
dofetilide (IKr blocker) treated rabbit ventricular myocytes accom-
panied by EAD elimination in hypertrophied cardiomyocytes in the 
same study. Some investigators failed to find any IKs activating 
effect of this compound [256], while others found the drug rescued 
repolarization in a guinea-pig cellular model of LQT2 syndrome 
[257]. However, according to the results of a recent study, the two 
enantiomers of L-364, 373 had opposing effects on IKs, explaining 
why the racemic drug was devoid of any IKs activating effect in 
other studies [258]. In order to properly investigate the putative 
beneficial effect of IKs activation in pathological settings with im-
paired repolarization reserve and arrhythmogenesis, additional IKs 
activator compounds need to be studied in different models of con-
genital and acquired models of prolonged repolarization. Impor-
tantly, further elucidation of the roles and tissue distribution of 
different KCNQ1 channel complexes formed with different regula-
tory -subunits are needed before meaningful cardiac selective IKs 
activator development becomes feasible [259]. 
 As discussed earlier, HF associated electrical remodeling in-
volves the downregulation of different potassium channels respon-
sible for repolarization, including Ito [20]. Impairment of the early 
phase of repolarization governed by Ito can lead to pathological 
alterations in calcium homeostasis, reduced calcium-induced cal-
cium release and reduced contractility [260]. Therefore, the phar-
macological activation of Ito may be a suitable target for improving 
calcium homeostasis and increasing contractility in HF. A recently 
developed Ito activator, NS5806 (Fig. 6) increased Ito by 80% in 
canine epicardial right ventricular cells, only by 16% in endocardial 
cells, and increased peak Ito in atrial myocytes by 25% [261]. Im-
portantly, in the same study NS5806 was found to strongly inhibit 
atrial INa, while the compound had little effect on ventricular INa 
[261]. The antianginal and INa, late inhibitor ranolazine exhibited 
efficacy against AF and this effect was attributed to its atrial selec-
tive INa blocking properties [262]. Therefore, it would be very inter-
esting to see whether NS5806 had any beneficial effect in an animal 
model of atrial fibrillation. In a canine model of rapid ventricular 
pacing induced heart failure, where reduced Ito density, slowed 
recovery of Ito from inactivation were observed, the Ito activator 
NS5806 increased Ito recovery from inactivation and restored the 
action potential notch in epicardial cells [263], leading the authors 
to conclude that some aspects of HF induced electrical remodeling 
can be reversed by pharmacological activation of Ito.  
 It is important to note that there are differences in the antiar-
rhythmic effects of these novel voltage gated potassium channel 
activators, and some exhibited proarrhythmic effects in certain ani-
mal models, therefore more, sufficiently detailed studies are needed 
to elucidate the cellular cardiac electrophysiological effects of these 
compounds to assess their effects on other ionic currents. 
 Another approach to APD prolongation limitation and facilita-
tion of repolarization is the pharmacological activation of sar-
colemmal KATP channels to activate steady-state, voltage-indepen-
dent potassium current. Figure 7 illustrates that activation of sar-
colemmal KATP can indeed reduce the dispersion of repolarization 
between canine ventricular papillary muscle and Purkinje fibers 
elicited by selective IKr block at slow pacing frequences [170]. 
Pharmacological activators of KATP have been shown to protect 
against arrhythmias induced by triggered activity, EADs and DADs 
[264-266]. The KATP opener nicorandil reduced EADs, shortened 
monophasic action potential duration and prevented syncope recur-
rence in patients with congenital LQT and in animal models of LQT 
[267-269]. Pharmacological activation of KATP can reduce calcium 
overload and improve contractile function [270], and at least in 
part, this protective mechanism involves resting membrane poten-
tial hyperpolarization and reduction in reverse-mode NCX activity 
[271-272]. 
 However, the activation of sarcolemmal KATP can lead to proar-
rhythmic side effects, most likely due to excessive APD shortening 
[273-274]. In a recent optical mapping study the KATP openers dia-
zoxide and pinacidil decreased APD and promoted burst pacing 
induced arrhythmias in coronary-perfused human atria and ventri-
cles isolated from failing hearts [275]. To reduce myocardial 
ischemia induced sarcolemmal KATP activation that can result in 
increased dispersion of repolarization between cardiac tissue re-
gions with different degrees of ischemia, the cardioselective inhibi-
tion of KATP channels has been proposed [276]. In addition, the 
presently available sarcolemmal KATP openers are not selective for 
cardiac KATP channels and activate vascular smooth muscle KATP 
channels, reducing total peripheral resistance and decreasing blood 
pressure [170] that can lead to reflex tachycardia. Therefore, car-
diac sarcolemmal KATP activators are needed to properly assess the 
antiarrhythmic and proarrhythmic effects of cardiac sarcolemmal 
KATP activation in different pathological settings. The different 
molecular composition of sarcolemmal KATP channels in different 
tissue types certainly suggest that this aim can be achieved [277-
278]. 
 In summary, KATP channel activation can be both antiarrhyth-
mic and proarrhythmic based on actual cardiac pathological settings 
and degree of ischemia, and the inhibition of sarcolemmal KATP has 
been suggested as an ischemia selective antiarrhythmic therapeutic 
modality. The detailed discussion of the role of KATP channels in 
cardiac arrhythmias is beyond the scope of this paper and the reader 
is referred to a recent review [170] and an update on this topic in 
this issue [279]. 
IKur Blockers 
 The atrial specific ultrarapidly activating IKur channel [164, 280] 
has been identified as a very promising target for drug development 
for the atrial selective pharmacological treatment of AF with little 
or no ventricular side effects. In line with these expectations, a large 
number of IKur inhibitor compounds have already been developed 
and tested in different experimental models in the last 15 years. The 
comprehensive discussion of these compounds is well beyond the 
scope of this review and the reader is referred to an excellent re-
 
 
 
 
 
Fig. (6). Chemical structure of the IKs activator L-364, 373 and Ito activator NS5806. 
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view on this topic [281]. It is important to note, however, that the 
selective inhibition of these channels by pure IKur blockers might be 
somewhat disappointing, since downregulation of IKur in prolonged 
AF has been reported [149, 151, 282]. 
IK, ACh Inhibitors 
 GIRK1 and GIRK4 channels conducting acetylcholine-
activated potassium current, IK, ACh, can be found predominantly in 
the atria [283], and they mediate the effects of vagal nerve stimula-
tion on the atria via M2 receptors and can induce AF [284]. The 
activation of these channels shortens atrial APD, atrial effective 
refractory period and hyperpolarizes the resting membrane potential 
- all these effects favour the stabilization of AF rotors and promot-
ing re-entry. The constitutive activation of these channels in AF has 
been shown [159], therefore their inhibition is expected to abolish 
AF. Indeed, the application of a derivative of the honey bee venom 
toxin tertiapin, tertiapin-Q inhibited constitutive IK, ACh in nanomo-
lar concentrations [285] and was shown to terminate AF in a canine 
aconitine-induced AF model [286]. Subsequently, the IK, ACh block-
ing effects and efficacy in experimental AF were reported for a 
series of novel compounds, including NIP-141, NIP-142, NIP-151 
and NTC-801 [287-290]. Some of these compounds inhibit other 
ionic currents also targeted in the treatment of AF, such as the al-
ready discussed IKur [291]. It is not known yet, however, whether 
these compounds influence ventricular contractility that would in-
terfere with their beneficial effects against AF in the setting of re-
duced left ventricular function, and few data is available on their 
effects on chronic AF with atrial remodeling. 
NCX Inhibitors 
 The Na+/Ca2+ exchanger is upregulated and its function is en-
hanced in HF and AF [192-193]. Increased NCX activity can con-
tribute a significant inward current leading to the development of 
DADs in HF [130]. In a canine heart failure model, inhibition of 
NCX led to normalization of cellular calcium handling [292], and 
inhibition of the NCX by SEA-0400 (Fig. 8) prevented EADs and 
DADs in dog ventricular tissue [293]. However, previously avail-
able NCX blockers lacked selectivity, most importantly they also 
blocked ICa, L [294], making it very difficult to separate the relative 
contribution of their NCX blocking and calcium channel blocking 
effects to the observed results. A very recent publication introduced 
a novel NCX blocker compound with improved selectivity for the 
NCX over ICa, L, ORM-10103 (Fig. 8) [295]. With the identification 
of this compound it now seems to be feasible to more critically 
assess the physiological role of the NCX in calcium homeostasis, as 
well as the effect of NCX inhibition on arrhythmias in the setting of 
HF. 
If Blockers 
 An association between elevated resting heart rate and in-
creased risk of mortality has been established in heart failure pa-
tients [296]. Therefore, reduction of elevated heart rate in HF pa-
tients seems beneficial. Moreover, the increased HCN2 and HCN4 
expression in human failing ventricular and atrial cardiomyocytes 
may contribute to abnormal ectopic activity and trigger arrhythmias 
in HF [184-186]. In theory, isoform selective If blockers could pre-
vent the triggering activity in HF occurring through HCN2 and 
HCN4 pathological activation. The most prominent representative If 
blocker compound, ivabradine is approved for the treatment of 
angina pectoris in patients who do not tolerate beta adrenergic 
blockers [297]. In pooled data from the BEAUTIFUL and SHIFT 
trials, in patients with reduced left ventricular function and elevated 
heart rate, ivabradine decreased HF associated hospitalization and 
cardiovascular mortality [298]. Ivabradine is a reasonably selective 
If current blocker [299], however, additional ion channel blocking 
effects of ivabradine have been identified that could contribute to 
its antiarrhythmic activity [300]. Recently, some important steps 
have been made in the development of new If blockers showing 
relative isoform selectivity [301], and EC18 was identified as a 
selective HCN4 blocker that slowed the slope of diastolic depolari-
zation in canine Purkinje fibers [302]. Further studies are needed, 
however, to determine the effects of isoform selective If blockers on 
enhanced triggered activity in experimental HF. 
Potential Candidates with Combined Mechanism of Action: the 
Way Forward? 
 The development of most of the compounds discussed so far 
have been following the concept of creating relatively selective ion 
channel blockers for the treatment of arrhythmias. However, sober-
ing lessons learnt from clinical trials following selective sodium 
and potassium channel blocker administration in patients with re-
duced left ventricular function [57-58], and the exceptional efficacy 
of amiodarone suggests that novel antiarrhythmic drugs with modu-
latory effects on multiple ion channels may exert beneficial effects 
in the treatment of atrial and ventricular arrhythmias. 
Dronedarone 
 Dronedarone is a new multichannel blocker antiarrhythmic drug 
approved for the treatment of AF. The drug was developed as an 
amiodarone structural analogue without the iodine moiety in an 
effort to reduce the serious extracardiac side effects of chronic 
 
 
 
 
 
 
 
 
Fig. (7). The cardiac sarcolemmal KATP channel activator pinacidil reduces reverse use-dependent repolarization prolongation and dispersion of repolarization 
following the administration of the IKr blocker dofetilide in canine Purkinje fibers and papillary muscle. Please note the large difference in cycle length de-
pendent repolarization prolongation in the two preparations. APD90: action potential duration at 90% repolarization. Reproduced from [170] with permission. 
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amiodarone treatment [48]. Dronedarone blocks IKr, IKs, IK1, Ito, INa 
and ICa, L [303]. However, dronedarone was found later in the PAL-
LAS clinical trial to increase heart failure events [52], and in the 
ANDROMEDA trial to increase mortality in patients with severely 
impaired left ventricular function [50]. Therefore, dronedarone is 
not recommended to treat arrhythmias in patients with structural 
heart disease and reduced left ventricular function [33]. 
Vernakalant 
 Vernakalant is a recently introduced antiarrhythmic drug that is 
relatively atrial specific and blocks several ionic currents, such as 
IKur, Ito, IK, ACh and INa [304], and was developed for the treatment of 
AF. Following intravenous administration, vernakalant effectively 
converted AF to sinus rhythm in recent onset and postoperative AF 
[305-307]. In a recent clinical trial oral vernakalant was found to be 
effective for maintaining sinus rhythm following cardioversion of 
AF [308]. Vernakalant does not exhibit proarrhythmic effects in 
dogs with chronic atrioventricular block, a model featuring IKs 
downregulation, bradycardia and increased susceptibility to ar-
rhythmias [309]. No proarrhythmic adverse effects were found in a 
rabbit proarrhythmia model [310] or in a recent clinical trial [308]. 
In AF associated with HF, vernakalant appears to be less effective 
for cardioversion and increased incidence of serious hypotensive 
episodes and ventricular arrhythmias were detected in patients with 
left ventricular dysfunction [311]. Vernakalant is currently ap-
proved in Europe for the conversion of recent onset AF. 
 The complex etiology of AF and the multiple mechanisms re-
sponsible for the development and maintenance of AF led to the 
suggestion that novel compounds targeting several pathways in-
volved in AF may exhibit improved efficacy [312-313]. In this 
regard, resveratrol, an intensively investigated red grape polyphenol 
that possesses cardioprotective properties [216] could serve as a 
potential parent compound for the development of future drugs to 
treat both AF and heart failure associated ventricular arrhythmias. 
Resveratrol has been shown to inhibit NFAT activation [314], a 
pathway implicated in AF [315] and pathological cardiac hypertro-
phy [316]. Resveratrol also inhibited hypertrophic remodeling 
[317], as well as late INa with preference over peak INa [218]. In-
deed, in a very recent study Compound 1 (C1; Fig. 9), a resveratrol 
derivative was shown to possess multi-channel blocking properties 
and exhibited efficacy against AF in a chronic atrial tachypacing 
induced atrial fibrillation dog model [233]. This novel compound 
inhibited peak and late IKur (IC50: 0.36 and 0.11 mol/l, respec-
tively), IK, ACh (IC50: 1.9 mol/l), peak INa and INa, late (IC50: 3.0 and 
1 mol/l, respectively), demonstrated NFAT inhibitory and antioxi-
dant properties that were similar to those of resveratrol. Impor-
tantly, C1 showed only weak hERG channel inhibition and did not 
prolong the QT interval in conscious dogs, suggesting that the com-
pound did not significantly influence ventricular repolarization and 
was unlikely to provoke ventricular arrhythmias. Based on these 
effects, it was concluded that C1 as a multifunctional small mole-
cule targeting several key pathways involved in the development 
and maintenance of AF. 
IV. SUMMARY 
 Heart failure and atrial fibrillation are the “two new epidemics 
of cardiovascular disease” [18]. Both HF and AF are associated 
with significant morbidity and mortality and their prevalence 
icreases with age. The two conditions are often diagnosed together 
and the development of the other condition further deteriorates the 
prognosis. Almost half of HF patients die due to ventricular fibrilla-
tion, and AF leads to increased mortality due to increased risk for 
stroke and heart failure. Both chronic HF and AF lead to structural 
and electrical remodeling of the heart that can significantly alter 
targets for pharmacological antiarrhythmic treatment. Current 
pharmacological approaches for the management of HF associated 
ventricular arrhythmias and AF lack efficacy and often lead to seri-
ous cardiovascular and/or extracardiac adverse events. For the 
treatment of ventricular arrhythmias in HF, novel approaches may 
include improving electrical remodeling impaired repolarization 
capacity via the activation of selected potassium currents and/or 
inhibition of abnormal depolarizing currents, normalization of im-
paired conduction and improving dysfunctional intracellular cal-
cium homeostasis. Future pharmacological treatment of AF may 
focus on atrial selective modulation of ionic currents to avoid ven-
tricular side effects and targeting other mechanisms involved in AF 
generation and maintenance with multifunctional compounds, with 
particular attention paid to avoid adverse effects in patients with left 
ventricular dysfunction. However, the upstream treatment of both 
conditions aiming at the reduction of disease induced remodeling is 
also emphasized. Due to the heterogenous mechanisms involved in 
ventricular and atrial arrhythmia development, it is expected that 
 
 
 
 
 
Fig. (8). Chemical structures of the Na+/Ca2+ exchanger inhibitors SEA-0400 and ORM-10103. 
 
 
 
 
 
 
 
 
 
Fig. (9). Chemical structures of resveratrol and Compound 1 (C1). 
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compounds with multiple mechanisms of action may show im-
proved efficacy in the treatment of arrhythmias in heart failure. 
ABBREVIATIONS 
AF = Atrial fibrillation 
APD = Action potential duration 
Cx43 = Connexin 43 
HF = Heart failure 
IK1 = Inwardly rectifying potassium current 
IKr = Rapid component of the delayed rectifier potas-
sium current 
IKs = Slow component of the delayed rectifier potas-
sium current 
IKur = Ultra-rapidly activating potassium current 
Ito = Transient outward potassium current 
INa, L = Late or persistent sodium current 
IKATP = Adenosine-triphosphate sensitive potassium cur-
rent 
IK, ACh = Acetylcholine-regulated potassium current 
NCX = Na+/Ca2+ exchanger 
SCD = Sudden cardiac death 
TdP = Torsades de Pointes 
VF = Ventricular fibrillation 
Vmax = Maximum rate of depolarization 
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